Continuing Education
for Urology & GU Oncology Clinicians

Conference Coverage: SUO 2019 Prostate

Washington, DC (UroToday.com) As has been highlighted in the morning symposium at the 2019 Society of Urologic Oncology Annual Meeting, research provides the opportunity for urologists and urologic oncologists to expand their sphere of influence beyond clinical catchment areas and beyond their years of practice. However, to do so requires methodologically robust research. To this end, the Society of Urologic Oncology arranged a plenary session focused on the “Statistical Implications on Urologic Cancer”. While an understanding of statistical methodology is important for those undertaking research, it is also important for the critical interpretation of the published literature, a task that all urologists will undertake.

Non-Accredited

Washington, DC (UroToday.com) At the Young Urologic Oncologists (YUO) Dinner Program Dr. Gennady Bratslavsky discussed keys to failing forward from a research perspective. Dr. Bratslavsky started by quoting Dr. John C. Maxwell, noting “[Failing forward is the key to] turning mistakes into stepping stones for success". Dr. Bratslavsky also notes five additional definitions for failing forward:

Non-Accredited

Washington, DC (UroToday.com)  At the 20th annual SUO conference, Dr. Adam Kibel reviewed results from neoadjuvant trials for localized high-risk prostate cancer. The optimal management for high-risk localized cancer has focused on the management of local disease through surgery, radiation therapy (RT), and multimodal therapy. But, deaths in this clinical entity occur from metastatic disease, and the treatment paradigm has recently shifted toward systemic treatment of micro-metastatic disease.

Non-Accredited

Washington, DC (UroToday.com) At the 20th Annual Meeting of the Society of Urologic Oncology, Dr. Martin Gleave reviewed findings of the genomic umbrella neoadjuvant study (GUNS) and other biomarker trials. Older neoadjuvant androgen deprivation therapy (ADT) studies showed improved pathologic surrogates (4-8% pathologic cure rate (pCR)) but no difference in PSA recurrence rates.1 Similarly, newer neoadjuvant trials using LHRH with abiraterone or enzalutamide or both showed improved pCR rates, 8%.

Non-Accredited

Washington, DC (UroToday.com) Molecular-based PET imaging for prostate cancer is transforming the ability to detect and target previously unknown sites of disease. While 18F-fluciclovine (Axumin®) PET-CT is approved for use in the United States and recommended by the National Comprehensive Cancer Network (NCCN), prostate-specific membrane antigen (PSMA) PET-CT is more widely used in Europe/Australia and is recommended by the European Association of Urology (EAU).1  

Non-Accredited